2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118920
    SQ 26655 82337-14-2 98%
    SQ 26655 is a TxA2 receptor agonist. SQ 26655 induces human platelet aggregation.
    SQ 26655
  • HY-119145
    MRS2496 491611-67-7 98%
    MRS2496 is a selective P2Y1 receptor antagonist with an IC50 value of 1.5 μM, exhibiting antiplatelet aggregation activity. MRS2496 can be used in the research of antiplatelet aggregation and blood-related diseases.
    MRS2496
  • HY-119195
    I5B2 93768-49-1 98%
    I5B2 is an angiotensin I converting enzyme inhibitor (IC50=0.091 μM) that can be isolated from the culture medium of Actinomycete actininadura sp. No. 937ZE-1. I5B2 can be used in the study of hypertension.
    I5B2
  • HY-119220
    Granotapide 594842-13-4 98%
    Granotapide is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces the absorption of cholesterol and triglycerides by inhibiting MTP. Granotapide can be used in the research of coronary artery disease, obesity, diabetes mellitus and hypertension.
    Granotapide
  • HY-119410
    Linotroban 120824-08-0
    Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent.
    Linotroban
  • HY-119497
    SB251023 208842-53-9 98%
    SB251023 is a β3-adrenergic receptor agonist with pEC50 values of 7.14 and 6.91 for the β3a- and β3b-adrenergic receptors, respectively. SB251023 is capable of modulating cyclic AMP levels and extracellular acidification rate (EAR) in cells. It has potential application value in the study of cardiovascular diseases and metabolic-related disorders.
    SB251023
  • HY-119511
    Isopentaquine 529-73-7 98%
    Isopentaquine is an orally active antimalarial agent. Isopentaquine induces mild morphological changes in the exoerythrocytic stage of Plasmodium fallax, with a ED50 of 6.7 mg/L. Isopentaquine causes degenerative changes in the development of Plasmodium oocysts in infected mosquitoes. Isopentaquine reduces the infectivity of Plasmodium falciparum gametocytes. Isopentaquine impairs sympathetic cardiovascular reflexes. Isopentaquine decreases the recurrence rate and total disease duration of Plasmodium vivax infection. Isopentaquine can be used in malaria-related research.
    Isopentaquine
  • HY-119613
    Clociguanil 3378-93-6 98%
    Clociguanil (BRL 50216), a DHFR inhibitor (IC50: 55.6 nM), is an antimalarial agent. Clociguanil has sympathomimetic and antiarrhythmic action.
    Clociguanil
  • HY-119750
    Budralazine 36798-79-5 98%
    Budralazine is a vasodilator, which dilates the vascular smooth muscle and exhibits hypotensive efficacy. Budralazine inhibits the central sympathetic nerve and exhibits an anti-tachycardic effect.
    Budralazine
  • HY-120164
    Glycerophospho-N-oleoyl ethanolamine 201738-24-1 98%
    Glycerophospho-N-oleoyl ethanolamine (GNOE) is a serum metabolite. Glycerophospho-N-oleoyl ethanolamine can be used to study Bicuspid aortic valve (BAV) disease.
    Glycerophospho-N-oleoyl ethanolamine
  • HY-120180
    BMS-188107 139232-80-7 98%
    BMS-188107 is a calcium antagonist that exerts anti-ischemic effects. BMS-188107 improves postischemic contractile function and reduces lactate dehydrogenase release. BMS-188107 can be utilized in cardiovascular research.
    BMS-188107
  • HY-120221
    SE 175 258278-64-7 98%
    SE 175 is an organic nitrate compound that acts as an NO donor in vivo following reductive transformation of the nitrate group to nitric oxide. SE 175 stimulates endothelial soluble guanylate cyclase and induces aortic vasorelaxation with an EC50 of 0.20 µM.
    SE 175
  • HY-120238
    RG 13647 145543-03-9 98%
    RG 13647 is an AT2-selective ligand. RG 13647 is an analog of PD 123177 (HY-121767). RG 13647 shows weak activity in competing for [125I]angiotensin II binding with an IC50 value of 100 μM. RG 13647 can be used for research of cardiovascular disease.
    RG 13647
  • HY-120586
    SC-46944 120729-15-9 98%
    SC-46944 is an orally active renin inhibitor and can be used for study of hypertension.
    SC-46944
  • HY-120636
    P2Y1 antagonist 1 1555697-67-0 98%
    P2Y1 antagonist 1 (compound 10q) is a potent antagonist of P2Y1, with the IC50s of 1.1 nM and 0.24 μM in FLIPR assay and hPA assay, respectively. P2Y1 antagonist 1 plays an important role in antiplatelet research.
    P2Y1 antagonist 1
  • HY-120672
    LG 83-6-05 131602-24-9 98%
    LG 83-6-05 is an inhibitor for sodium channel. LG 83-6-05 can be used in the research about cardiac rhythm disorders.
    LG 83-6-05
  • HY-120756
    PD125754 124339-32-8 98%
    PD125754 is an oligopeptide renin inhibitor (IC50: 22 nM).
    PD125754
  • HY-120843
    WS009A 136286-49-2 98%
    WS009A is an antagonist for endothelin receptor (ET Receptor) with IC50 of 5.8 and 6.9 μM for ET-1 receptor and ET-2 receptor. WS009A can be used in research of cardiovascular diseases.
    WS009A
  • HY-120849
    Darapladib analog-1 1389264-17-8 98%
    Darapladib analog-1 (Compound 16) is an O-alkylated Darapladib (HY-10521). Darapladib analog-1 inhibits Lp-PLA2. Darapladib analog-1 can be used in the research of atherosclerosis.
    Darapladib analog-1
  • HY-12090R
    Anacetrapib (Standard) 875446-37-0 98%
    Anacetrapib (Standard) is the analytical standard of Anacetrapib. This product is intended for research and analytical applications. Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib (Standard)
Cat. No. Product Name / Synonyms Application Reactivity